Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder.

Ci ji yi xue za zhi = Tzu-chi medical journal Pub Date : 2019-04-02 eCollection Date: 2020-01-01 DOI:10.4103/tcmj.tcmj_226_18

Cheng-Ling Lee, Hueih-Ling Ong, Hann-Chorng Kuo

{"title":"Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder.","authors":"Cheng-Ling Lee, Hueih-Ling Ong, Hann-Chorng Kuo","doi":"10.4103/tcmj.tcmj_226_18","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was to evaluate the efficacy of mirabegron 25 mg daily in patients with nocturia-predominant hypersensitive bladder (HSB).Materials and methods: This study prospectively investigated 219 consecutive patients with nocturia-predominant HSB and treated with mirabegron 25 mg daily from July 2015 to 2016. Patient with nocturia episode decreased by ≥1/night after treatment was considered successful. The subjective symptom score, such as International Prostate Symptom Score (IPSS), Quality of life index, Overactive Bladder Symptom Score (OABSS), Urgency Severity Scale, patient perception of bladder condition (PPBC), and nocturia episodes per night, was assessed before and 1 month after mirabegron treatment and between successful and failed groups.Results: A total of 219 patients, including 51 women and 168 men, were enrolled. The mean age of the population was 72.3 ± 11.0 years. Totally, 58 (26.5%) of the patients had improvement in nocturia at 1 month after treatment. Among them, 14 (27.5%) women and 44 (26.2%) men had improvement in nocturia episodes after treatment (P = 0.858). Compared the clinical data between successful and failed group, the baseline symptom scores were more severe in successful group, including IPSS-storage subscore (4.84 ± 2.09 vs. 4.11 ± 2.19, P = 0.031), OABSS (3.21 ± 0.67 vs. 2.91 ± 1.00, P = 0.037), and nocturia episodes (3.81 ± 0.95 vs. 3.095 ± 1.32, P = 0.000). Multivariate analysis revealed only a higher nocturia episodes (P = 0.046) predict a successful treatment result. Mirabegron 25 mg daily significantly improved PPBC score along the 3 months' follow-up (P < 0.05), and postvoid residual volume did not increase after mirabegron treatment in overall patients.Conclusions: Mirabegron 25 mg daily treatment showed a limited therapeutic effect on nocturia-predominant HSB patients. The patients with higher OAB symptoms predict a successful result.","PeriodicalId":72593,"journal":{"name":"Ci ji yi xue za zhi = Tzu-chi medical journal","volume":"32 1","pages":"30-35"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/fa/TCMJ-32-30.PMC7015015.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ci ji yi xue za zhi = Tzu-chi medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tcmj.tcmj_226_18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The objective of this study was to evaluate the efficacy of mirabegron 25 mg daily in patients with nocturia-predominant hypersensitive bladder (HSB).

Materials and methods: This study prospectively investigated 219 consecutive patients with nocturia-predominant HSB and treated with mirabegron 25 mg daily from July 2015 to 2016. Patient with nocturia episode decreased by ≥1/night after treatment was considered successful. The subjective symptom score, such as International Prostate Symptom Score (IPSS), Quality of life index, Overactive Bladder Symptom Score (OABSS), Urgency Severity Scale, patient perception of bladder condition (PPBC), and nocturia episodes per night, was assessed before and 1 month after mirabegron treatment and between successful and failed groups.

Results: A total of 219 patients, including 51 women and 168 men, were enrolled. The mean age of the population was 72.3 ± 11.0 years. Totally, 58 (26.5%) of the patients had improvement in nocturia at 1 month after treatment. Among them, 14 (27.5%) women and 44 (26.2%) men had improvement in nocturia episodes after treatment (P = 0.858). Compared the clinical data between successful and failed group, the baseline symptom scores were more severe in successful group, including IPSS-storage subscore (4.84 ± 2.09 vs. 4.11 ± 2.19, P = 0.031), OABSS (3.21 ± 0.67 vs. 2.91 ± 1.00, P = 0.037), and nocturia episodes (3.81 ± 0.95 vs. 3.095 ± 1.32, P = 0.000). Multivariate analysis revealed only a higher nocturia episodes (P = 0.046) predict a successful treatment result. Mirabegron 25 mg daily significantly improved PPBC score along the 3 months' follow-up (P < 0.05), and postvoid residual volume did not increase after mirabegron treatment in overall patients.

Conclusions: Mirabegron 25 mg daily treatment showed a limited therapeutic effect on nocturia-predominant HSB patients. The patients with higher OAB symptoms predict a successful result.

查看原文本刊更多论文

米拉贝琼 25 毫克单药治疗夜尿为主的过敏性膀胱患者的疗效。

研究目的本研究旨在评估米拉贝琼 25 毫克/天对夜尿为主的高敏感性膀胱（HSB）患者的疗效：本研究对2015年7月至2016年连续219例夜尿症为主的HSB患者进行了前瞻性调查，并每日使用米拉贝琼25毫克进行治疗。治疗后夜尿次数减少≥1次/夜的患者为治疗成功。在米贝琼治疗前和治疗后1个月，以及成功组和失败组之间，评估了主观症状评分，如国际前列腺症状评分（IPSS）、生活质量指数、膀胱过度活动症状评分（OABSS）、尿急严重程度量表、患者对膀胱状况的感知（PPBC）和每晚夜尿次数：共有 219 名患者入组，其中女性 51 人，男性 168 人。平均年龄为（72.3 ± 11.0）岁。共有 58 名（26.5%）患者在治疗 1 个月后夜尿情况有所改善。其中，14 名女性（27.5%）和 44 名男性（26.2%）在治疗后夜尿次数有所改善（P = 0.858）。对比成功组和失败组的临床数据，成功组的基线症状评分更严重，包括IPSS-storage子分数（4.84 ± 2.09 vs. 4.11 ± 2.19，P = 0.031）、OABSS（3.21 ± 0.67 vs. 2.91 ± 1.00，P = 0.037）和夜尿症发作次数（3.81 ± 0.95 vs. 3.095 ± 1.32，P = 0.000）。多变量分析显示，只有较高的夜尿次数（P = 0.046）才能预测成功的治疗结果。在3个月的随访中，米拉贝琼每天25毫克可明显改善PPBC评分（P＜0.05），在米拉贝琼治疗后，所有患者的排尿后残余尿量均未增加：米拉贝琼每天 25 毫克的治疗对夜尿症为主的 HSB 患者的治疗效果有限。OAB症状较重的患者预示着治疗会取得成功。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ci ji yi xue za zhi = Tzu-chi medical journal

自引率

0.00%

发文量